Dataset from Capra D, Monti CB, Luporini AG, Lombardi F, Gumina C, Sironi A, Asti ELG, Bonavina L, Secchi F, Sardanelli F. Computed tomography-derived myocardial extracellular volume: an early biomarker of cardiotoxicity in esophageal cancer patients undergoing radiation therapy. Insights Imaging. 2020 Nov 23;11(1):120. doi: 10.1186/s13244-020-00922-2. PMID: 33226481; PMCID: PMC7683763.

Dataset from the article Capra D, Monti CB, Luporini AG, Lombardi F, Gumina C, Sironi A, Asti ELG, Bonavina L, Secchi F, Sardanelli F. Computed tomography-derived myocardial extracellular volume: an early biomarker of cardiotoxicity in esophageal cancer patients undergoing radiation therapy. Insights Imaging. 2020 Nov 23;11(1):120. doi: 10.1186/s13244-020-00922-2. PMID: 33226481; PMCID: PMC7683763. This is the abstract: Objectives: We aimed to assess extracellular volume (ECV) through non-gated, contrast-enhanced computed tomography (CT) before and after radiation therapy (RT) in patients with esophageal cancer (EC). Materials and methods: EC patients who had undergone CT before and after RT were retrospectively assessed. Patients with preexisting cardiovascular disease or with heavily artifacted CT were excluded. ECV was calculated using density values for the myocardial septum and blood pool. Data were reported as mean and standard deviation or median and interquartile range according to their distribution; t test or Wilcoxon and Pearson r or Spearman ρ were subsequently used. Results: Twenty-one patients with stage ≥ IB EC, aged 64 ± 18 years, were included. Mean and maximum RT doses were 21.2 Gy (16.9-24.1) and 42.5 Gy (41.8-49.2), respectively. At baseline (n = 21), hematocrit was 39% ± 4%, ECV 27.9% ± 3.5%; 35 days (30-38) after RT (n = 20), hematocrit was 36% ± 4%, lower than at baseline (p = 0.002), ECV 30.3% ± 8.3%, higher than at baseline (p = 0.081); at follow-up 420 days (244-624) after RT (n = 13), hematocrit was 36% ± 5%, lower than at baseline (p = 0.030), ECV 31.4% ± 4.5%, higher than at baseline (p = 0.011). No patients showed signs of overt cardiotoxicity. ECV early after RT was moderately positively correlated with maximum RT dose (ρ = 0.50, p = 0.036). Conclusions: In EC patients, CT-derived myocardial ECV was increased after RT and may thus appear as a potential early biomarker of cardiotoxicity.本数据集来自以下论文：Capra D、Monti CB、Luporini AG、Lombardi F、Gumina C、Sironi A、Asti ELG、Bonavina L、Secchi F、Sardanelli F 所著《计算机断层扫描衍生的心肌细胞外容积：接受放射治疗的食管癌患者心脏毒性早期生物标志物》，发表于《Insights Imaging》，2020年11月23日；11(1):120。DOI：10.1186/s13244-020-00922-2，PMID：33226481，PMCID：PMC7683763。 **研究目的**：本研究旨在通过放射治疗（radiation therapy, RT）前后的非门控增强计算机断层扫描（computed tomography, CT），评估食管癌（esophageal cancer, EC）患者的细胞外容积（extracellular volume, ECV）。 **材料与方法**：对接受RT前后CT检查的EC患者进行回顾性分析。排除既往存在心血管疾病或CT图像存在严重伪影的患者。通过心肌间隔与血液池的密度值计算ECV。根据数据分布特征，以均值±标准差或中位数（四分位数间距）的形式报告数据；后续分别采用t检验或Wilcoxon检验、Pearson相关系数或Spearman ρ秩相关系数进行统计学分析。 **研究结果**：本研究共纳入21例IB期及以上EC患者，年龄为64±18岁。患者的平均放射治疗剂量与最大放射治疗剂量分别为21.2 Gy（16.9~24.1 Gy）与42.5 Gy（41.8~49.2 Gy）。基线时（n=21），患者的血细胞比容为39%±4%，ECV为27.9%±3.5%；RT后35天（30~38天，n=20），患者血细胞比容为36%±4%，较基线降低（p=0.002），ECV为30.3%±8.3%，较基线升高（p=0.081）；RT后随访420天（244~624天，n=13），患者血细胞比容为36%±5%，较基线降低（p=0.030），ECV为31.4%±4.5%，较基线升高（p=0.011）。所有患者均未出现显性心脏毒性的临床表现。RT后早期的ECV与最大RT剂量呈中度正相关（ρ=0.50，p=0.036）。 **研究结论**：在EC患者中，CT衍生的心肌ECV在RT后出现升高，因此有望成为心脏毒性的潜在早期生物标志物。